Form 8-K - Current report:
SEC Accession No. 0001193125-25-019325
Filing Date
2025-02-03
Accepted
2025-02-03 16:46:03
Documents
17
Period of Report
2025-02-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d894576d8k.htm   iXBRL 8-K 28186
2 EX-5.1 d894576dex51.htm EX-5.1 13369
3 EX-10.1 d894576dex101.htm EX-10.1 212263
7 GRAPHIC g894576cm10-11.jpg GRAPHIC 3465
8 GRAPHIC g894576g0202235738630.jpg GRAPHIC 1810
  Complete submission text file 0001193125-25-019325.txt   456857

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apto-20250203.xsd EX-101.SCH 2855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apto-20250203_lab.xml EX-101.LAB 19467
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apto-20250203_pre.xml EX-101.PRE 12147
20 EXTRACTED XBRL INSTANCE DOCUMENT d894576d8k_htm.xml XML 3937
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 25583245
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)